RxDoctor Payments DataLook up a doctor →

Wesley White, MD

Urology · Knoxville, TNNPI 1730353780

Payments from drug & device makers

$23,803in general payments, 2019–2025

Across 443 payments — averaging $53.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$11K
  • Axonics, Inc.$2K
  • Boston Scientific$1K
  • Intuitive Surgical$913
  • Janssen Scientific Affairs, LLC$882
  • Astellas Pharma US Inc$790
  • plus $7K from 47 others

What the payments were for

  • Consulting fees$7586%
  • Travel & lodging$1,29310%
  • Food & beverage$11,06583%
  • Education$1871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,803 in reported general payments places this provider in the 85th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$522,452
Medicare patients
1,357
Services billed
11,244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide169$2,298,030
OrgovyxRelugolix443$1,149,293
NubeqaDarolutamide75$986,964
MyrbetriqMirabegron256$203,427
ErleadaApalutamide11$154,197
GemtesaVibegron58$50,079
Solifenacin Succinate194$16,631
PremarinEstrogens, Conjugated30$12,977
Tamsulosin Hcl865$12,713
Finasteride427$6,567
Potassium Citrate ErPotassium Citrate61$5,733
Alfuzosin Hcl ErAlfuzosin Hcl197$4,008
Testosterone Cypionate33$1,544
Silodosin13$1,509
Trimethoprim30$1,465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$790$2,501,457425 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$11,134$1,199,373501 claims
BayerNubeqa$290$986,96475 claims
Johnson & JohnsonErleada$759$154,19711 claims
PfizerPremarin$782$12,97730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 276 urology providers in Tennessee.

Other urology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →